Now On Demand: Understanding the Interplay Between Medicaid and 340B

A recent Manatt webinar focused on the complexities of the 340B program—and reviewed key findings from our 50-state survey on the interplay between 340B and Medicaid. Click here to view the webinar free on-demand (and earn CLE). Click here to download a free copy of the presentation and a new infographic highlighting key survey findings.

The 340B drug discount program—which requires drug manufacturers to provide outpatient drugs to eligible healthcare entities at sharply reduced prices—continues to expand, with the number of participating covered entities almost doubling in the past five years to 38,000, according to the Government Accountability Office. As the 340B program has grown, so has the controversy around it. Supporters believe that it is vital to helping hospitals and other covered entities care for their uninsured and underinsured patients, while critics assert that it is being abused.

Both sides can agree, however, that the program can be very confusing to navigate. The interplay between 340B and Medicaid can be particularly challenging, especially in states providing drug coverage through Medicaid managed care organizations (MCOs). The use of contract pharmacies adds to the complexities of identifying 340B drugs. 

In a recent webinar, Manatt focused on the complexities of the 340B program—and reviewed key findings from our comprehensive 50-state survey on the interplay between the 340B and Medicaid programs. We want to be sure you don’t miss any of the important information shared during the webinar. If you or anyone on your team were unable to attend the CLE-eligible webinar, click here to access the session free, on-demand. For a free copy of the webinar presentation, click here. The webinar answers key questions, including:

• What is the 340B program, and how does it work?
• What is the interplay between 340B and Medicaid—and what are the resulting challenges?
• How do contract pharmacy arrangements add to the complications?
• How much are states reimbursing 340B covered entities and contract pharmacies for 340B drugs?
• What methodologies are states employing to avoid duplicate discounts?

If you have any questions or issues you’d like to discuss after viewing the webinar, please contact Helen Pfister, Partner, Manatt Health, at [email protected] or 212.790.7277.

P.S. During the webinar, we shared highlights from our 50-state survey on 340B, analyzing how states reimburse 340B covered entities and contract pharmacies for 340B drugs, and the steps states are taking to avoid duplicate discounts. Click here to access a free infographic presenting key results.